- Genenta Science (GNTA, Financial) reports promising survival rates for Temferon in glioblastoma multiforme (GBM) patients, with a 29% two-year survival rate.
- Long-term study suggests potential disease progression control, with two patients surviving three years post-surgery.
- Genenta has launched a Phase 1 study for genitourinary tumors to explore Temferon's efficacy in combination with other therapies.
Genenta Science (GNTA) has announced encouraging long-term results from their TEM-GBM study of Temferon, a treatment for glioblastoma multiforme (GBM). Out of 38 enrolled patients, 25 received Temferon, with two significant milestones achieved—two patients have survived three years post-initial surgery. Notably, one patient displayed no disease progression, eliminating the need for second-line therapies, while the other experienced initial progression that stabilized without further treatment.
Key clinical outcomes highlighted a 29% two-year survival rate among patients with unmethylated MGMT, showing a median overall survival rate of 17 months. These results favorably compare to historical data, which show approximately a 14% two-year survival rate and a median survival of 13-15 months with standard treatments.
In addition, Genenta has initiated the TEM-GU Phase 1 study targeting genitourinary tumors, specifically Metastatic Renal Cell Carcinoma. This trial will investigate the combination of Temferon with immune checkpoint inhibitors or tyrosine kinase inhibitors. The trial aims to enroll 12 patients, utilizing a fixed dose based on prior safety data from GBM trials.
Furthermore, a scientific manuscript detailing Temferon's potential to enhance CAR-T activity has been accepted for publication in Science Translational Medicine. This recognition supports Temferon's innovative approach of reprogramming the tumor microenvironment to promote adaptive immune responses.
